Engineered immune cells called CAR-T cells are used in the treatment of cancer. Researchers from Uppsala University have now ...

Researchers found that bioengineered CAR-T cells when mixed with other immune cells can "donate" proteins, suggesting ...

VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy ...

Despite the powerful cancer-fighting capabilities of treatments based on CAR-T cells to fight a patient’s cancer, one key challenge is getting these treatments to more patients.

On this World Cancer Day, Chris Vogelsang, a cancer survivor from upstate New York, is celebrating his recovery thanks to a ...

CAR T-cell therapies have established themselves ... This allows for an assessment of the gene shuttle itself, the vector integration sites, i.e. the sites in the genome of the cells where the ...

Instead, the biotech focused on UB-VV400, an off-the-shelf, multidomain fusion protein surface-engineered lentiviral vector designed to generate CD22-directed CAR T cells within a patient’s body.

View Full Profile. Learn about our Editorial Policies. Chimeric antigen receptor (CAR) T cell therapy leverages patients’ immune systems to fight cancer. This immunotherapy greatly expanded treatment ...

CAR T-cell therapies have established themselves as a frequently very successful and overall promising treatment option for various blood cancers for which no other effective therapies are available.

CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a ...

Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the therapy itself caused any type of secondary cancer in the modified T cells, ...

CAR T–focused biotech Cargo Therapeutics surprised and disappointed analysts when it announced that it would discontinue a ...